Skip to main content
logo
Elite Pharmaceuticals, Inc. (ELTP)
OTCMKTS · Delayed Price · Currency is USD
0.3649
+0.0072 (2.01%)
Aug 7, 2026, 1:34 PM EST

Elite Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Apr - Mar.

Revenue & Profits
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
148.87148.8784.0456.6334.1632.26
Revenue Growth
77.13%77.13%48.42%65.79%5.87%27.11%
Gross Profit
75.0275.0240.0926.3616.5914.8
Operating Income
49.9649.9621.210.793.975.07
Net Income
44.8744.87-4.3120.113.568.9
Earnings Per Share
0.030.03-0.000.020.000.01
EPS Growth
---537.54%-57.99%81.05%

Cash & Debt
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
29.829.811.327.117.838.54
Total Debt
5.825.8210.9111.743.892.78
Net Cash (Debt)
23.9823.980.4-4.633.945.75
Net Cash Growth
5888.11%5888.11%---31.44%606.63%
Net Cash Per Share
0.020.020.00-0.000.000.01

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
23.7523.757.46-3.243.346.51
Capital Expenditures
-0.93-0.93-1.63-0.81-5.74-0.5
Free Cash Flow
22.8222.825.83-4.04-2.46.01
Free Cash Flow Growth
291.43%291.43%---109.85%

Margins
Chart
Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
50.40%50.40%47.70%46.55%48.58%45.86%
Operating Margin
33.56%33.56%25.23%19.05%11.62%15.72%
Pretax Margin
38.16%38.16%-0.06%0.82%11.67%22.20%
Profit Margin
30.14%30.14%-5.13%35.51%10.43%27.58%
FCF Margin
15.33%15.33%6.94%-7.14%-7.02%18.63%

Valuation
Chart
Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PE Ratio
11.928.64-7.818.263.97
P/FCF Ratio
16.8816.9979.70--5.88
PS Ratio
2.592.615.532.770.861.10